ATE312095T1 - Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden - Google Patents

Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden

Info

Publication number
ATE312095T1
ATE312095T1 AT00960258T AT00960258T ATE312095T1 AT E312095 T1 ATE312095 T1 AT E312095T1 AT 00960258 T AT00960258 T AT 00960258T AT 00960258 T AT00960258 T AT 00960258T AT E312095 T1 ATE312095 T1 AT E312095T1
Authority
AT
Austria
Prior art keywords
compounds
carboxic
acylsulfonamides
acids
treatment methods
Prior art date
Application number
AT00960258T
Other languages
English (en)
Inventor
Patrick Lacombe
Marc Labelle
Rejean Ruel
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of ATE312095T1 publication Critical patent/ATE312095T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00960258T 1999-09-14 2000-09-13 Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden ATE312095T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15390399P 1999-09-14 1999-09-14
PCT/CA2000/001058 WO2001019819A2 (en) 1999-09-14 2000-09-13 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment

Publications (1)

Publication Number Publication Date
ATE312095T1 true ATE312095T1 (de) 2005-12-15

Family

ID=22549208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00960258T ATE312095T1 (de) 1999-09-14 2000-09-13 Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden

Country Status (9)

Country Link
US (1) US6369082B1 (de)
EP (1) EP1216241B1 (de)
JP (1) JP2003509420A (de)
AT (1) ATE312095T1 (de)
AU (1) AU772841B2 (de)
CA (1) CA2384782A1 (de)
DE (1) DE60024648T2 (de)
ES (1) ES2250182T3 (de)
WO (1) WO2001019819A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
CA2440374A1 (en) * 2001-03-14 2002-09-19 Takayuki Maruyama A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient
JPWO2003024484A1 (ja) * 2001-09-14 2004-12-24 小野薬品工業株式会社 掻痒症治療剤
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
EP2123273B1 (de) 2007-02-16 2013-10-23 ONO Pharmaceutical Co., Ltd. Therapeutisches mittel gegen harnausscheidungsstörungen
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
EP2831293B1 (de) 2012-03-30 2020-05-13 Tata Steel IJmuiden BV Verfahren zur herstellung eines erholungsgeglühten beschichteten stahlsubstrats zur verpackung von anwendungen und verpackungsstahlprodukt
EP2671873A1 (de) 2012-06-06 2013-12-11 Solvay Sa Verfahren zur Zyklisierung von Hydrazinacrylsäurederivaten
EP2671874B1 (de) 2012-06-06 2016-01-13 Solvay Sa Herstellung von 1-substitutierten 3-Fluoralkyl-pyrazol-4-carboxylsäure-Estern
ES2620826T3 (es) 2012-07-13 2017-06-29 Tata Steel Ijmuiden Bv Procedimiento para producir un sustrato revestido con polímero para aplicaciones de envasado y un sustrato revestido con polímero producido mediante el mismo
AU2014369916A1 (en) 2013-12-24 2016-06-16 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598775B2 (en) 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
US4829081A (en) 1986-01-07 1989-05-09 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4927851A (en) 1986-01-07 1990-05-22 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
EP0799218B1 (de) 1994-12-21 2003-02-19 Merck Frosst Canada & Co. Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
WO1997016442A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
WO2001019819A2 (en) 2001-03-22
CA2384782A1 (en) 2001-03-22
DE60024648T2 (de) 2006-08-10
WO2001019819A3 (en) 2001-09-20
AU7264100A (en) 2001-04-17
DE60024648D1 (de) 2006-01-12
EP1216241A1 (de) 2002-06-26
EP1216241B1 (de) 2005-12-07
AU772841B2 (en) 2004-05-06
US6369082B1 (en) 2002-04-09
JP2003509420A (ja) 2003-03-11
ES2250182T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
ATE259795T1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
SE9903544D0 (sv) Novel compounds
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
MXPA04003245A (es) Hidroxipropilaminas.
PT1427708E (pt) Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os
BR0206955A (pt) Ligantes de receptores de canabinóides
WO2001019776A3 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
DE60024648D1 (de) Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
SE0402925D0 (sv) Novel Compounds
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MXPA05013607A (es) Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos.
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
SE0004827D0 (sv) Therapeutic compounds
AP9801417A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders.
AU2002362008A1 (en) Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties